Definitive chemoradiotherapy and consolidation durvalumab for locally advanced non-small cell lung cancer: A multicenter retrospective study
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000041483
- Lead Sponsor
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University
- Brief Summary
[Primary endpoint: Incidence and risk factor of symptomatic radiation pneumonitis (RP)] 146 patients were analyzed. The median follow-up period was16 months. A majority of the patients had stage III disease (86%), received radiation doses of 60-66 Gy equivalent in 2 Gy fractions (93%) and CBDCA and PTX/Nab-PTX (77%), and underwent ENI (71%) and 3D-CRT(75%). The 12-month incidence of grade 2+ RP was 34.4% [95% CI; 26.7-42.1%]. In the multivariable analysis, lung V20 was a significant risk factor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 146
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who received concurrent durvalumab, had received anti-PD-1 or PD-L1 inhibitors, or had received chest irradiation except whole breast irradiation for breast cancer.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence and risk factors of symptomatic radiation pneumonitis
- Secondary Outcome Measures
Name Time Method Overall survival, Progression-free survival, Failure pattern, Incidence of other severe toxicities, Proportion of patients who receive durvalumab after definitive chemoradiotherapy